IL327381A - טיפול לטיפול בסוכרת סוג 1 באמצעות מעכבי rock2 וdyrk1- - Google Patents

טיפול לטיפול בסוכרת סוג 1 באמצעות מעכבי rock2 וdyrk1-

Info

Publication number
IL327381A
IL327381A IL327381A IL32738126A IL327381A IL 327381 A IL327381 A IL 327381A IL 327381 A IL327381 A IL 327381A IL 32738126 A IL32738126 A IL 32738126A IL 327381 A IL327381 A IL 327381A
Authority
IL
Israel
Prior art keywords
alkyl
group
11aro
21ar11arn
cycloalkyl
Prior art date
Application number
IL327381A
Other languages
English (en)
Original Assignee
Graviton Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graviton Pharmaceuticals B V filed Critical Graviton Pharmaceuticals B V
Publication of IL327381A publication Critical patent/IL327381A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL327381A 2023-09-28 2024-09-30 טיפול לטיפול בסוכרת סוג 1 באמצעות מעכבי rock2 וdyrk1- IL327381A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363586192P 2023-09-28 2023-09-28
PCT/IB2024/059567 WO2025069008A1 (en) 2023-09-28 2024-09-30 Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors

Publications (1)

Publication Number Publication Date
IL327381A true IL327381A (he) 2026-05-01

Family

ID=93257597

Family Applications (1)

Application Number Title Priority Date Filing Date
IL327381A IL327381A (he) 2023-09-28 2024-09-30 טיפול לטיפול בסוכרת סוג 1 באמצעות מעכבי rock2 וdyrk1-

Country Status (6)

Country Link
EP (1) EP4784127A1 (he)
KR (1) KR20260099122A (he)
CN (1) CN122341372A (he)
AU (1) AU2024352423A1 (he)
IL (1) IL327381A (he)
WO (1) WO2025069008A1 (he)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005723A1 (fr) 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
US7410975B2 (en) 2003-06-20 2008-08-12 Coley Pharmaceutical Group, Inc. Small molecule toll-like receptor (TLR) antagonists
US7547779B2 (en) 2003-10-06 2009-06-16 Glaxo Group Limited Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
JP4857128B2 (ja) 2004-02-20 2012-01-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規な化合物
DE102004017438A1 (de) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
PT1905452E (pt) 2005-07-12 2013-07-16 Kowa Co Agente para a prevenção ou tratamento do glaucoma
US20110021776A1 (en) 2006-08-28 2011-01-27 Medipropharma, Inc. Compositions for the treatment of central nervous system diseases and disorders
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
GB0705566D0 (en) 2007-03-23 2007-05-02 Univ Dundee Method of treating learning impairment in down's syndrome subjects
FR2919608B1 (fr) 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
KR20100010894A (ko) 2008-07-23 2010-02-02 가부시키가이샤 키노파마 Dyrk를 저해하는 화합물을 함유하는 의약 조성물
EP2266562A1 (en) 2009-06-23 2010-12-29 Centre National de la Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
AU2010298440B2 (en) 2009-09-22 2016-05-19 Neuronascent, Inc Methods and pharmaceutical compositions for treating down syndrome
WO2011041655A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
US9221808B2 (en) 2010-04-16 2015-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use
JP5565705B2 (ja) 2011-01-17 2014-08-06 Jx日鉱日石エネルギー株式会社 脱硫器
US20120184542A1 (en) 2011-01-19 2012-07-19 Kevin Anderson Pyrido pyrimidines
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
KR102006749B1 (ko) 2011-08-19 2019-08-02 디악쏘니 Dyrk1 억제제 및 이의 용도
RS63503B1 (sr) 2012-10-05 2022-09-30 Kadmon Corporation Llc Inhibitori rho kinaze
US11311541B2 (en) 2014-04-09 2022-04-26 Kadmon Corporation, Llc Treatment of GVHD
PL3558321T3 (pl) 2016-12-23 2023-10-23 Felicitex Therapeutics, Inc. Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
CN112969694B (zh) 2018-11-09 2023-06-13 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途
CN113490493B (zh) 2019-03-01 2024-10-29 北京泰德制药股份有限公司 治疗脂肪性肝病和/或脂肪性肝炎的方法
TWI804743B (zh) 2019-06-25 2023-06-11 大陸商北京泰德製藥股份有限公司 治療特發性肺纖維化的方法
WO2021064141A1 (en) 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
US20230303534A1 (en) 2020-08-31 2023-09-28 Beijing Tide Pharmaceutical Co., Ltd. Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method
CN118772118A (zh) 2020-08-31 2024-10-15 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途
AU2022341315A1 (en) * 2021-09-13 2024-05-02 Provention Bio, Inc. Methods and compositions comprising anti-cd3 antibodies and dyrk1a inhibitors for treating diabetes
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
US20250289807A1 (en) 2022-04-29 2025-09-18 Graviton Bioscience Bv Inhibitors of ROCK2
EP4622973A1 (en) 2022-11-21 2025-10-01 Graviton Bioscience BV Inhibitors of rock2
CN116355832A (zh) * 2023-03-24 2023-06-30 四川大学华西医院 尿液上皮样细胞来源的iPSCs诱导分化制备人胰腺β细胞的方法和用途

Also Published As

Publication number Publication date
KR20260099122A (ko) 2026-06-26
AU2024352423A1 (en) 2026-05-14
EP4784127A1 (en) 2026-08-05
WO2025069008A1 (en) 2025-04-03
CN122341372A (zh) 2026-07-03

Similar Documents

Publication Publication Date Title
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
TW200505439A (en) Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight loss agents
CY1107484T1 (el) Παραγωγα γκελνταναμυκινης χρησιμοποιουμενα για τη θεραπεια καρκινου
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
MX2009012197A (es) Metodos para tratamiento de ulceras en la piel.
TW200507833A (en) Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
PH12022553501A1 (en) Alk2 inhibitors for the treatment of anemia
GB202003059D0 (en) Compounds for use in a method of treating, preventing and/or reducing the symptoms of pain
MX2023011633A (es) Inhibidores de sos1 e inhibidores de ras para su uso en el tratamiento del dolor.
MA69153A1 (fr) Méthodes de traitement d'une splénomégalie
MX2022007113A (es) Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.
IL308152A (he) 2-פלואורואלקיל-4,3,1-אוקסאדיאזול-5-איל-תיאזול, מעכבי hdac6 לשימוש בטיפול במחלה מטבולית ו hfpef
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
EP4157241A4 (en) AGENTS AND METHODS FOR THE TREATMENT OF TAUOPATHIES
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
EP4445914A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS AND USE
MX2024015040A (es) Fitusiran para el tratamiento de la hemofilia a y b en pacientes pediatricos
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
WO2023196584A3 (en) Endocytosis inhibitors and their use for pain treatment
CA3305368A1 (en) Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
IL327385A (he) מעכבי rock2 בטיפול בהשמנה